about
Turning-Off Signaling by Siglecs, Selectins, and Galectins: Chemical Inhibition of Glycan-Dependent Interactions in CancerStructural Basis for Galectin-1-dependent Pre-B Cell Receptor (Pre-BCR) ActivationThe anti-angiogenic peptide anginex disrupts the cell membrane.Dynamic Contrast Enhanced Magnetic Resonance Imaging in Oncology: Theory, Data Acquisition, Analysis, and ExamplesThe clinical application of angiostatic therapy in combination with radiotherapy: past, present, future.Angiostatic peptides use plasma fibronectin to home to angiogenic vasculatureScheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization.Transactivation of the receptor-tyrosine kinase ephrin receptor A2 is required for the low molecular weight hyaluronan-mediated angiogenesis that is implicated in tumor progression.Galectin-1 links tumor hypoxia and radiotherapy.Polycationic calixarene PTX013, a potent cytotoxic agent against tumors and drug resistant cancer.Enhancement of T-cell-mediated antitumor response: angiostatic adjuvant to immunotherapy against cancer.Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulvenEvaluation of hypoxia in a feline model of head and neck cancer using ⁶⁴Cu-ATSM positron emission tomography/computed tomography.The anti-angiogenic peptide anginex greatly enhances galectin-1 binding affinity for glycoproteins.Anti-angiogenic peptides for cancer therapeuticsGalectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapyThiodigalactoside inhibits murine cancers by concurrently blocking effects of galectin-1 on immune dysregulation, angiogenesis and protection against oxidative stress.3D tumor tissue analogs and their orthotopic implants for understanding tumor-targeting of microenvironment-responsive nanosized chemotherapy and radiation.Investigation the Possibility of Using Peptides with a Helical Repeating Pattern of Hydro-Phobic and Hydrophilic Residues to Inhibit IL-10.NMR solution structure of the angiostatic peptide anginex.The involvement of Galectins in the modulation of the JAK/STAT pathway in myeloproliferative neoplasiaFibronectin as target for tumor therapy.Radiation-induced galectin-1 by endothelial cells: a promising molecular target for preferential drug delivery to the tumor vasculatureInterfering with Gal-1-mediated angiogenesis contributes to the pathogenesis of preeclampsia.Blood outgrowth endothelial cells increase tumor growth rates and modify tumor physiology: relevance for therapeutic targeting.An Amphiphilic Peptide Induces Apoptosis Through the miR29b-p53 Pathway in Cancer CellsRadiation-enhanced therapeutic targeting of galectin-1 enriched malignant stroma in triple negative breast cancer.Paramagnetic and fluorescent liposomes for target-specific imaging and therapy of tumor angiogenesis.Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment.Tumour vasculature targeting agents in hybrid/conjugate drugs.Pre-B cell receptor binding to galectin-1 modifies galectin-1/carbohydrate affinity to modulate specific galectin-1/glycan lattice interactions.Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib.Structure-activity relationships of the human prothrombin kringle-2 peptide derivative NSA9: anti-proliferative activity and cellular internalization.Design of a partial peptide mimetic of anginex with antiangiogenic and anticancer activity.Beta-sheet is the bioactive conformation of the anti-angiogenic anginex peptidePeptides derived from human decorin leucine-rich repeat 5 inhibit angiogenesis.Galectin Targeted Therapy in Oncology: Current Knowledge and Perspectives.Urokinase-derived peptide UP-7 suppresses tumor angiogenesis and metastasis through inhibition of FAK activation.Combination of anginex gene therapy and radiation decelerates the growth and pulmonary metastasis of human osteosarcoma xenografts.Galectins as Molecular Targets for Therapeutic Intervention.
P2860
Q26744538-B8BA97A5-BAB7-44B7-93E9-FEF52B1BCD3AQ27674972-6F5F44BD-4881-41F4-9248-5C9AD7A72E54Q30159968-F4E7326D-0565-4AF5-B532-25AFE6751951Q33510695-CA5DADBE-E9B4-4B59-9766-254BD8DC0BFAQ33705268-EA584FCD-68AA-423D-8B94-1437A13FB724Q33837087-C81F2899-F7DF-4790-A8B4-417B7A354714Q34039409-034AD26D-B85F-43CC-85B1-5A3FCE24D955Q34107144-DB2C7634-CD0E-4C73-BFDC-156260FC944AQ34129297-AF3595BD-29D1-42A4-9F02-BF505768911EQ34564225-6D7E5676-3AD1-483B-A66F-47778CD392E1Q34564433-CC9E8CD4-6281-4803-A3D0-E82E7B919F1CQ34589227-E01B3411-17F6-474C-870D-D357B5AF5D64Q34696310-AF2D9F9F-1FE8-4A4A-A39D-4005864BF86EQ34799812-C7D2DCB6-830F-4E1D-803C-39C1918255BFQ35043016-F50A27EC-10D9-4D59-9A09-50B1E021FE06Q35127584-E965BFC0-6A9F-4D97-8A4A-0DEA47DBC71AQ35161285-11A832BE-BCB0-4F9D-9DB1-9689BF4188D0Q35994548-40C5DAF9-E9CA-46D0-8E65-44B30F7DE638Q35995841-71D0C31D-1C64-447D-965F-6322BA693558Q36003263-118637BE-6C8C-4AF1-BE11-3C3CA75256CCQ36062042-7892BDB3-F837-4E70-BDFE-9F1BB10658BEQ36354769-5D5EC5E1-0597-40CB-A4D5-A13839B55F8CQ36652864-4258F2B4-78A7-4C29-AB4B-6713B078E47BQ37010679-6FBC17DE-58DB-4837-A1D6-65711992A6ACQ37061740-C064C07B-D68D-451B-868D-64530F1C67ABQ37238932-DA94F17D-538F-42DC-872F-EA8AE8669A2BQ37520289-FEC183E8-729B-4411-8B4E-C4262A60B64DQ37730633-351688F5-2B17-466D-8789-F249BE0BAB57Q38019412-19D6C8B8-8DF5-4FD9-AF9A-801A36668843Q38094627-7EFAC00A-A268-4536-B6DD-96C757911707Q38906800-FEA7E51B-9AC3-4006-8C92-600B4384A515Q39104708-7A760787-ED1D-49EB-8DD3-D7EEBE29CE29Q40334510-B7BD7676-F91D-44A9-9BEB-EC91CA724060Q40639238-611417DD-2A35-4BBE-8D69-32EBE2F5BF63Q42143434-5283CD4F-86B8-4BF2-83CD-5C7481F5A2AAQ46516361-7852EE54-695F-4D9F-B916-2038239DEB0DQ48270428-9A5EE914-7B01-4AB9-9395-CD97CECA3608Q52668185-1F0AB460-B67D-4D3D-900F-18ECA81555A6Q55283741-BAE0CACD-CCDD-4D48-ABBB-B64E5B29B9F3Q55316400-F2094047-849E-49E2-9C4B-9ABC0BC33685
P2860
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Anginex, a designed peptide that inhibits angiogenesis.
@en
type
label
Anginex, a designed peptide that inhibits angiogenesis.
@en
prefLabel
Anginex, a designed peptide that inhibits angiogenesis.
@en
P2093
P2860
P1433
P1476
Anginex, a designed peptide that inhibits angiogenesis.
@en
P2093
A F Barendsz-Janson
A W Griffioen
D W van der Schaft
H A Struijker Boudier
H F Hillen
P2860
P304
P356
10.1042/0264-6021:3540233
P407
P577
2001-03-01T00:00:00Z